Evidence map›Paper›PMID 35117442›Full record

ArticleTranslational cancer research2020

Treatment and prognosis for patients with differentiated thyroid carcinoma bone metastases.

Shiqi Wang, Juanzhang Luo, Zhaoming Zhong, Xiao Qi, Ting Liu, Rujia Qin, Zaili Zhao, Yan Xi, Ruimei Sun, Yaohong Wu and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Shiqi WangDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Juanzhang LuoDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Zhaoming ZhongDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Xiao QiDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Ting LiuDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Rujia QinDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Zaili ZhaoDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Yan XiDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Ruimei SunDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Yaohong WuDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Chuanzheng SunDepartment of Head & Neck Surgery Section II, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate reasonable treatment modalities and prognostic factors for patients with differentiated thyroid carcinoma (DTC) bone metastases (BM).

methodsThe clinicopathological characteristics and follow-up data for all patients with DTC BM who received treatment in the Third Affiliated Hospital of Kunming Medical University between November 1, 1993 and December 31, 2016 were analyzed retrospectively with respect to mortality and survival rates. Multivariate analysis was performed using the Cox proportional hazard model.

resultsThe 5- and 10-year overall survival (OS) rates were 51.5% and 17.2%, respectively, for all 60 patients. Univariate analysis showed that patients diagnosed with BM at <45 years of age, with controlled thyroid-stimulating hormone (TSH) levels and those undergoing surgery or

conclusionsPatients with DTC BM have poor prognoses. Age at diagnosis with BM <45 years old, undergoing surgery for bone lesions, and not receiving chemotherapy were independent factors of favorable prognosis for patients with DTC BM.

Indexed as

bone metastases (BM)differentiated thyroid carcinoma (DTC)Head and neck cancerprognosistreatment

Identifiers

PMID35117442
PMCPMC8798784
OpenAlexW2999026906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.